

# Attracting Innovation




Healthworld Oct.5, 2022

George Tousimis, Country Director Greece & Cyprus



# The value of innovation



Source: Riley (2005), Clio Infra (2015), and UN Population Division (2019) OurWorldInData.org/life-expectancy • CC BY  
Note: Shown is period life expectancy at birth, the average number of years a newborn would live if the pattern of mortality in the given year were to stay the same throughout its life.

Pharmaceutical innovation is responsible

for **35%** (This is 1.7 years)

of the life expectancy increase from 1990 to 2015 due to advancements in therapies of

- HIV
- Breast cancer
- Cardiovascular diseases

Source: Contributions Of Public Health, Pharmaceuticals, And Other Medical Care To US Life Expectancy Changes, 1990-2015, Jason D. Buxbaum, Michael E. Chernew, A. Mark Fendrick, and David M. Cutler, VOL. 39, NO. 9 HEALTH AFFAIRS


# The success recipe for innovation



## Incentives

---


- To attract innovation.
- To be a better choice than other countries



## Sustainability

---

- To be viable as an investment



## Predictability

---



- To remain viable
- To plan future steps with lower risk

# How do we score?





## Incentives

- Incentives for pharma investment included in RRF
- Current incentive scheme not attractive enough for clinical trials




## Sustainability

- Total paybacks reaching 70% for serious disease drugs
- Inequality between drugs & patients
- Revert price pressure to volume control



## Predictability

- Frequent and retrospective changes of framework harm long-term planning
- Very limited data transparency



# What do we need?



## IMMEDIATE MEASURES

- 1 Avoid negative surprises**  
freeze implementation of the budget split which creates inequalities between patients
- 2 Increase funding** to depict more realistically the demand for medicines

## STRUCTURAL MEASURES

- 4 Activate Pharma expenditure monitoring** committee
- 5 Prioritize volume control** reforms (Therapeutic protocols & link to e-prescription) with **clear timelines**
- 6 Monitor execution** in a transparent manner based on data sharing and horizon scanning



Let's do things right for patients in need

